2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
1451 1
Ultima descărcare din IBN:
2023-01-28 19:39
SM ISO690:2012
KNUUTI, Juhani, REVENCO, Valeriu. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. In: European Heart Journal, 2020, vol. 41, pp. 407-477. ISSN 0195-668X. DOI: https://doi.org/10.1093/eurheartj/ehz425
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
European Heart Journal
Volumul 41 / 2020 / ISSN 0195-668X

2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes

DOI:https://doi.org/10.1093/eurheartj/ehz425

Pag. 407-477

Knuuti Juhani1, Revenco Valeriu2
 
1 Turku University Hospital, Turku,
2 Moldavian Society of Cardiology
 
 
Disponibil în IBN: 13 octombrie 2020


Rezumat

Coronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive interventions designed to achieve disease stabilization or regression. The disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event caused by plaque rupture or erosion. However, the disease is chronic, most often progressive, and hence serious, even in clinically apparently silent periods. The dynamic nature of the CAD process results in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic coronary syndromes (CCS). The Guidelines presented here refer to the management of patients with CCS. The natural history of CCS is illustrated in Figure 1.

Cuvinte-cheie
angina pectoris, Anti-ischaemic drugs, Antithrombotic therapy, Chronic coronary syndromes, coronary artery disease, Diagnostic testing, Guidelines, imaging, Lifestyle modifications, Lipid-lowering drugs, Microvascular angina, Myocardial ischaemia, myocardial revascularization, risk assessment, screening, Vasospastic angina